Table 1.
Baseline characteristics of all study patients
| Multiple myeloma (N = 210) | Lymphoma (N = 350) | All patients (N = 560) | |
|---|---|---|---|
| Disease (%) | |||
| Multiple myeloma | 210 (100) | Na | 210 (37.5) |
| Indolent NHL | Na | 92 (26.3) | 92 (16.4) |
| Aggressive NHL | Na | 197 (56.3) | 197 (35.2) |
| Hodgkin’s lymphoma | Na | 61 (17.4) | 61 (10.9) |
| Median age at collection—years (range) | 58 (31–69) | 52 (14–71) | 55 (14–71) |
| Gender —no. (%) | |||
| Male | 131 (62.4) | 209 (59.7) | 340 (60.7) |
| Female | 79 (37.6) | 141 (40.3) | 220 (39.3) |
| Disease status at mobilization—no. (%) | |||
| CR | 9 (4.3) | 53 (15.1) | 62 (11) |
| PR | 62 (29.5) | 75 (21.4) | 137 (24.5) |
| Chemosensitive | 17 (8.1) | 22 (6.3) | 39 (7) |
| Rel-ref | 4 (1.9) | 139 (39.7) | 143 (25.5) |
| Unknown | 118 (56.2) | 61 (17.4) | 179 (32) |
| No. chemotherapy lines prior to collection (%) | |||
| 1 | 185 (88.1) | 168 (48) | 353 (63) |
| 2 | 9 (4.3) | 140 (40) | 149 (26.6) |
| ≥3 | 2 (1) | 38 (10.6) | 40 (7.1) |
| Unknown | 14 (6.7) | 4 (1.1) | 18 (3.2) |
| Mobilization regimen—no. (%) | |||
| Cyclo-G | 206 (98.1) | 165 (47.1) | 371 (66.3) |
| DHAP-G | 0(0) | 102 (29.1) | 102 (18.2) |
| ICE-G | 0(0) | 32 (9.1) | 32 (5.7) |
| Other chemotherapy-GSF | 0(0) | 18 (5.1) | 18 (3.2) |
| Plerixafor | 2 (1) | 23 (6.6) | 25 (4.5) |
| Other | 2 (1) | 10 (2.9) | 12 (2.1) |
| No. prior collections (%) | |||
| 0 | 203 (96.7) | 336 (96) | 539 (96.3) |
| 1 | 6 (2.9) | 14 (4) | 20 (3.6) |
| 2 | 1 (0.5) | 0(0) | 1 (0.1) |
| Median CD34+ counts—×10 6 cells/kg (range) | |||
| Pre-collection | 4.02 (0.29–38.97) | 2.61 (0–63.11) | 3.12 (0–63.11) |
| Total collected | 8.15 (1.05–32.67) | 5.59 (0.32–58.77) | 6.41 (0.32–58.77) |
Cyclo-G cyclophosphamide and G-CSF, DHAP-G dexamethasone, cytarabine, cisplatinum, G-GCSF, ICE-G ifosfamide, carboplatin, etoposide, G-CSF, CR complete remission, PR partial remission, Rel-ref relapse refractory